Maxim Group began coverage on shares of Silexion Therapeutics (NASDAQ:SLXN – Free Report) in a report published on Friday morning, Benzinga reports. The brokerage issued a buy rating and a $1.00 target price on the stock.
Silexion Therapeutics Price Performance
Shares of NASDAQ SLXN opened at $0.25 on Friday. The firm has a 50 day simple moving average of $0.66. Silexion Therapeutics has a 1 year low of $0.23 and a 1 year high of $4.65.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last released its quarterly earnings results on Thursday, August 29th. The company reported ($5.87) earnings per share (EPS) for the quarter.
About Silexion Therapeutics
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
Recommended Stories
- Five stocks we like better than Silexion Therapeutics
- Why Invest in 5G? How to Invest in 5G Stocks
- Intel: Is Now the Time to Be Brave?
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Bank Stocks – Best Bank Stocks to Invest In
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
